Immatics, Anderson launch Immatics US to develop multiple T-cell and TCR-based adoptive cellular therapies
Immatics believes that ACT approaches to be developed by the new company can achieve a step change in the treatment of cancer, by delivering significant, long-lasting clinical benefits.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.